Symbols

Aclaris Therapeutics 2025 Q3 Earnings Widened Losses Amid Positive Clinical Results

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team

Friday, Nov 7, 2025 4:34 am ET1min read

Aime Summary

- Aclaris Therapeutics (ACRS) reported Q3 2025 losses amid positive Phase 2a trial results for ATI-2138 and strong cash runway through 2028.

- Revenue declined due to reduced licensing income from Sun Pharma and Eli LillyLLY-- agreements compared to prior milestones.

- Earnings per share fell to -$0.12, while post-earnings stock outperformed the SPY ETF despite widened losses.

- Analysts maintained a "buy" rating consensus, citing clinical progress and long-term financial stability despite short-term setbacks.

Aclaris Therapeutics (ACRS) reported third-quarter 2025 earnings on November 6, 2025, . , . Management highlighted positive Phase 2a trial results for ATI-2138 and a robust cash runway through 2028.

Revenue

, . The drop reflects reduced licensing revenue from the Sun Pharma and Eli Lilly agreements compared to earlier milestones.

Earnings/Net Income

, . Earnings per share (EPS) turned to a loss of $0.12, . .

Post-Earnings Price Action Review

. , . This outperformed the SPY ETF, .

. , .

CEO Commentary

Dr. , . , .

Guidance

. , respectively.

Additional News

Recent non-earnings updates include a “buy” consensus, . . Additionally, .

Ainvest Earnings Report Digest

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue